Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis
Authors' conclusion
Liraglutide therapy improved BMI, insulin sensitivity and menstrual regularity in overweight or obese women with PCOS, suggesting concurrent metabolic and reproductive benefits.
Study context
- Population
- Overweight or obese women with polycystic ovary syndrome (PCOS); databases searched from inception to 31 May 2025
- Participants
- 330 participants7 randomized controlled trials (RCTs)
- Comparison
- Liraglutide vs placebo, metformin or non-liraglutide active treatments
- Outcome
- Metabolic and reproductive outcomes
Methodological detailsrandom-effects model, Two reviewers independently conducted study selection, data extraction and risk-of-bias assessment
- Random-effects model
- Two reviewers independently conducted study selection, data extraction and risk-of-bias assessment
Pooled result
As reported in the abstract
Liraglutide vs ControlEstimate (95% CI)
High heterogeneity
Hedges' g (menstrual frequency) 1.76(0.28–3.24)
Metabolic and reproductive outcomes
Hedges' g (BMI) −0.52(−0.94 to −0.10)
Improved with liraglutide
Hedges' g (HOMA-IR) −0.52(−0.83 to −0.22)
Further pooled results
Ovulation and pregnancy
- Could not be pooled due to insufficient reporting
Safety
Adverse events
- Liraglutide generally well tolerated; AEs mainly mild gastrointestinal symptoms
Original publication
Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta‐analysis. Diabetes Obes Metab. Published 9 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →